Ambroxol Hydrochloride is a defined ionic salt form offering distinct advantages in pharmaceutical processing and performance over the free acid or base. The counter-ion in Ambroxol Hydrochloride has been selected based on toxicological acceptability at daily intake levels achievable from the proposed dosage regimen, and compatibility with the drug product excipient matrix. Solid-state characterisation of Ambroxol Hydrochloride includes polymorph screening, stability under accelerated conditions, and determination of hygroscopic behaviour that may affect powder processing, fill weight uniformity, and long-term chemical stability in the drug product.
The OEB assigned to Ambroxol Hydrochloride in pharmaceutical manufacturing is determined by structured potency banding based on its pharmacological target, NOAEL from repeat-dose studies, genotoxic classification under ICH M7, and reproductive toxicant status.
